one of the major issues in cancer radiotherapy (Rt) is normal tissue toxicity. introduction of radiosensitizers like gold nanoparticles (Gnps) into cancer cells to enhance the local Rt dose has been tested successfully. However, it is not known how Gnps interact with other stromal cells such as normal fibroblasts (FBs) and cancer associated fibroblasts (CAFs) within the tumour microenvironment. It is known that FBs turn into CAFs to promote tumour growth. Hence, we used FBs and CAFs along with HeLa (our cancer cell line) to evaluate the differences in GNP uptake and resulting radiation induced damage to elucidate the GNP-mediated therapeutic effect in RT. The CAFs had the largest uptake of the GNPs per cell, with on average 265% relative to HeLa while FBs had only 7.55% the uptake of HeLa and 2.87% the uptake of CAFs. This translated to increases in 53BP1-related DNA damage foci in CAFs (13.5%) and HeLa (9.8%) compared to FBs (8.8%) with RT treatment. This difference in DNA damage due to selective targeting of cancer associated cells over normal cells may allow GNPs to be an effective tool in future cancer RT to battle normal tissue toxicity while improving local Rt dose to the tumour. Cancer is a family of diseases arising from dysregulation of the expression of multiple genes, leading to abnormal cell proliferation and cell death. As a result, there is significant morbidity in patients if left untreated 1. Before the age of 75, about 1 in 6 people will develop cancer while 1 in 9 will die from it 2. Aside from surgery, one of the main modalities employed in the treatment of cancer is radiotherapy (RT). RT aims to deliver high doses of ionizing radiation to cancerous tissue, inducing death from damage to important structures such as the DNA or mitochondria 3. Despite being used in 50% of all patients diagnosed with cancer, one of the major issues in current RT modalities is the normal tissue toxicity in radiosensitive tissue localized closely with the cancer 4,5. Furthermore, there are many radiobiological hurdles to overcome, such as the influence of cancer stem cells, tumour heterogeneity, tumour hypoxia, metabolic pathways, and other complications, that will increase the radioresistance of the tumour cells 6-8. While the introduction of targeting methods such as volumetric modulated arc therapy (VMAT) and image guided radiotherapy (IGRT) has improved the efficacy of RT, there is a limit of improvement when it comes to the use of RT as a singular treatment modality 9. In an effort towards reducing the normal tissue toxicity while increasing the damage to the tumour, radiosensitizers have been introduced 10. Radiosensitizers work via various pathways, such as targeting of the radioresistant hypoxic cells in tumours, or through production of reaction oxygen species (ROS) 10,11. The introduction of high atomic number materials into tumour tissue has been explored as a promising approach to enhance the local radiation dose 12-17 .